Advertisement

PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 8–8 | Cite as

Avelumab promising cost-effective option for Merkel cell carcinoma

Clinical study

Reference

  1. Bullement A, et al. Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. PharmacoEconomics-Open : 24 Jan 2019. Available from: URL: https://doi.org/10.1007/s41669-018-0115-y

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations